Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES

Background  AVERROES, a randomized controlled trial in high-risk patients with atrial fibrillation, unsuitable for vitamin K antagonist therapy, demonstrated efficacy and safety of apixaban compared with aspirin. At the conclusion of the double-blind phase, an open-label extension was initiated to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Benz, Alexander P., Eikelboom, John W., Yusuf, Salim, Hohnloser, Stefan H., Kahl, Anja, Beresh, Heather, Balasubramanian, Kumar, Healey, Jeff S., Connolly, Stuart J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982299/
https://www.ncbi.nlm.nih.gov/pubmed/33011964
http://dx.doi.org/10.1055/s-0040-1717115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982299/
https://www.ncbi.nlm.nih.gov/pubmed/33011964
http://dx.doi.org/10.1055/s-0040-1717115

Ejemplares similares